5 Abilify Diabetes Lawsuits Dismissed By New York Court For Forum Non Conveniens
(November 11, 2015, 9:18 AM EST) -- NEW YORK — A New York state court justice on Oct. 23 dismissed five Abilify diabetes cases on the grounds of forum non conveniens provided defendants Bristol-Myers Squibb Co. (BMS) and Otsuka America Pharmaceutical Inc. stipulate to being sued in alternative fora (Cheyenne Beth Confer v. Bristol-Myers Squibb Company, et al., No. 158295/2014, N.Y. Sup., New York Co.; 2015 N.Y. Misc. LEXIS 3853).